caa a22 4500 445335475 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1645-z doi (NATIONALLICENCE)springer-10.1245/s10434-011-1645-z COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma [Elektronische Daten] [Yasunori Akutsu, Naoyuki Hanari, Gulbostan Yusup, Aki Komatsu-Akimoto, Norimasa Ikeda, Mikito Mori, Yasuo Yoneyama, Satoshi Endo, Yukimasa Miyazawa, Hisahiro Matsubara] Purpose: The overexpression of cyclooxygenase (COX)2 is correlated with carcinogenesis, tumor progression, and prognosis, and increased COX2 expression is correlated with radiation resistance. However, no correlation between the COX2 expression and resistance to chemoradiotherapy for esophageal squamous cell carcinoma has been characterized. The purpose of the present study was to evaluate whether COX2 expression is an indicator of resistance to chemoradiotherapy in esophageal squamous cell carcinoma and the feasibility of COX2 as a biomarker for CRT. Methods: Fifty-eight patients who were diagnosed with esophageal squamous cell carcinoma from biopsy samples were enrolled in the present series. All patients underwent concurrent chemoradiotherapy in a neoadjuvant setting, followed by radical esophagectomy. COX2 expression was evaluated by immunohistochemical staining and statistically compared with the histopathologic findings in surgically resected specimens. Results: The rate of responders was 87% for weak expression of COX2, 62% for moderate expression, and 30% for strong expression, and there was a close correlation between COX2 expression and the response rate (Kendall's τb=0.396, P=0.001). In the univariate analysis, negative or weak expression of COX2 was found to correlate significantly with CRT response (odds ratio, 6.296; 95% confidence interval (CI), 1.58-25.096; P=0.010). In the multivariate analysis, weak expression of COX2 (30% or less) was found to be an independent prognostic factor (odds ratio, 6.534; 95% CI, 1.535-27.803; P=0.011). Conclusions: The COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma, and it also is a feasible biomarker for evaluating the CRT response. Society of Surgical Oncology, 2011 Akutsu Yasunori Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Hanari Naoyuki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Yusup Gulbostan Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Komatsu-Akimoto Aki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Ikeda Norimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Mori Mikito Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Yoneyama Yasuo Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Endo Satoshi Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Miyazawa Yukimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Matsubara Hisahiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2946-2951 1068-9265 18:10<2946 2011 18 10434 https://doi.org/10.1245/s10434-011-1645-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1645-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Akutsu Yasunori Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Hanari Naoyuki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Yusup Gulbostan Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Komatsu-Akimoto Aki Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Ikeda Norimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Mori Mikito Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Yoneyama Yasuo Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Endo Satoshi Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Miyazawa Yukimasa Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 700 1- Matsubara Hisahiro Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 2946-2951 1068-9265 18:10<2946 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer